Monopar Therapeutics Inc. announced the upcoming presentation of new data on the long-term neurological efficacy and safety of ALXN1840 for Wilson disease at the 150th American Neurological Association Annual Meeting.
The analysis included pooled efficacy outcomes from three independent clinical trials and safety data from a fourth trial, totaling 255 and 266 patients respectively.
The data to be presented highlights sustained neurological improvement and psychiatric outcomes, along with ALXN1840's favorable safety profile.
Sustained Neurological Improvement
Statistically significant neurologic improvement was sustained over 6 years based on the UWDRS scale.
Crossover Benefit
Patients transitioning to ALXN1840 from standard care showed additional neurological improvement, reversing prior deterioration.
Psychiatric Outcomes
Significant psychiatric improvement was sustained over multiple years according to the BPRS scale.
Consistency Across Trials
Neurological benefits were consistently observed across multiple independent studies.
Favorable Safety Profile
Less than 1% of patients experienced drug-related neurological serious adverse events during over 645 patient-years on ALXN1840.
- The new data on ALXN1840's long-term efficacy and safety for Wilson disease presented at the ANA emphasizes its potential for addressing both neurological and hepatic manifestations of the condition.
- These findings complement the previously showcased hepatic and systemic efficacy data, underlining the versatility of ALXN1840 in treating Wilson disease.
Overall, the data presented at the 150th ANA Annual Meeting sheds light on the promising long-term benefits and safety profile of ALXN1840, offering hope for Wilson disease patients and validating Monopar's commitment to innovation in biopharmaceuticals.